
|Articles|March 9, 2010
- December 2009
- Volume 0
Do Insurers Spend Too Much on Administration and Too Little on Care?
Author(s)Onclive Team
Advertisement
Articles in this issue
almost 16 years ago
Amgen Honored for Best Pipeline & Best New Drugalmost 16 years ago
The Effect of New Treatments on Cancer-related Bone Lossalmost 16 years ago
Exercise Maintains Function, Improves QoL for Patients With Lymphomaalmost 16 years ago
Continuing Education Opportunities on the Webalmost 16 years ago
News Briefs & FDA Updatesalmost 16 years ago
News & Opinionalmost 16 years ago
Decline in Cancer Deaths No Reason to Get ComplacentAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































